Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FOXO TechnologiesFOXOD +15.61% EV-to-EBITDA is -1.30 as of Aug. 17, 2026. The stock has 4 warning signs investors should review. Among 510 Healthcare Providers & Services companies, FOXO Technologies ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, FOXO Technologies's enterprise value is $12.09 Mil.
FOXO Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.32 Mil. Therefore, FOXO Technologies's EV-to-EBITDA for today is -1.30.
The historical rank and industry rank for FOXO Technologies's EV-to-EBITDA or its related term are showing as below:
FOXOD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.8 Med: -1.95 Max: -1.26
Current: -1.3
During the past 6 years, the highest EV-to-EBITDA of FOXO Technologies was -1.26. The lowest was -4.80. And the median was -1.95.
FOXOD's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.685
vs FOXOD: -1.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
FOXO Technologies's PE Ratio (TTM) for today is calculated as:
FOXO Technologies's share price for today is $0.04.
FOXO Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1145.745.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for FOXO Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, FOXO Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FOXO Technologies EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, FOXO Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where FOXO Technologies's EV-to-EBITDA falls into.
FOXO Technologies's current Enterprise Value is $12.09 Mil.
FOXO Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FOXO Technologies (FOXOD) has a EV-to-EBITDA of -1.30 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on FOXO Technologies. According to the industry distribution chart, FOXO Technologies ranks #999999 out of 510 companies in the Healthcare Providers & Services industry.
Is FOXO Technologies' EV-to-EBITDA too high?
FOXO Technologies' current EV-to-EBITDA is -1.30. Based on the distribution chart, FOXO Technologies ranks #999999 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does FOXO Technologies' EV-to-EBITDA compare to NHLG and BACK?
According to the Healthcare Providers & Services industry distribution chart, FOXO Technologies ranks #999999 out of 510 companies for EV-to-EBITDA. This places FOXO Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 10.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.69, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on FOXO Technologies. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FOXO Technologies's current EV-to-EBITDA is -1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FOXO Technologies stock overvalued right now?
FOXO Technologies (FOXOD) has a current EV-to-EBITDA of -1.30. The current EV-to-EBITDA is -1.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For FOXO Technologies (FOXOD), the current EV-to-EBITDA is -1.30 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FOXO Technologies Inc is a healthcare services and technology company. It currently operates four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. The Company manages and classifies its business into three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs. Myrtle, RCHI and SCCH operate under the Healthcare segment and Vector operates under the Life Science Services segment. The company generates majority of its revenue from Healthcare segment. It includes RCHI's hospital, BSF, has 25 inpatient beds, and a 24/7 emergency department and provides ancillary services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOXOD has been successfully added to your 
